It’s the 2nd buyout in as many days for the Abbott Park, Ill.-based healthcare giant, which yesterday said it plans to pay $5.8 billion for point-of-care diagnostics maker Alere.
Kalila, which is based in Campbell, Calif., won 510(k) clearance from FDA for the Vado device in April 2014, about 4 months after landing CE Mark approval in the European Union.
“Atrial fibrillation is a serious condition that increases the risk of stroke and causes severe symptoms in many patients, but remains undertreated today because current technologies have limited effectiveness,” electrophysiology GM Michael Pederson said in prepared remarks. “With this acquisition, Abbott gains a unique technology to expand our portfolio of tools for the treatment of atrial fibrillation and other heart rhythm disorders. We look forward to initiating the launch of this innovative sheath in the United States and Europe in the coming weeks.”
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.